Why hesitation about hip replacement is almost universal

Putting off a major operation is not a character flaw — it is a reasonable response to uncertainty. Most people who begin asking seriously about hip replacement have already spent months or years managing pain through physiotherapy, anti-inflammatories, walking aids, and injections. By the time surgery enters the conversation, the hesitation is rarely simple cold feet; it is layered with exhaustion, conflicting information, and a perfectly understandable reluctance to hand yourself over to an operating theatre.

What is worth examining is whether the specific fears driving that hesitation reflect current reality or an older picture of what hip replacement involves. The operation has one of the longest evidence bases in elective surgery and a well-documented safety record — yet many patients carry mental models formed by outdated statistics, second-hand accounts, or news stories that are far from representative of routine outcomes.

This article works through several distinct hesitation clusters — fear of the operation itself, concern about dislocation, worry about being too young, worry about being too old, questions about what recovery actually looks like, and the underappreciated cost of prolonged delay — treating each as a separate question that deserves a straight answer rather than a blanket reassurance.

Fear of the operation itself: what the risks actually look like

Fear of not waking up is not irrational — it is visceral, and Liam Gallagher has said publicly that it was precisely this concern that kept him from the operating theatre longer than it should have. That feeling deserves a straight answer, not a dismissal.

Hip replacement is one of the most commonly performed elective operations globally, with decades of accumulated safety data. For patients who have been appropriately screened and medically optimised beforehand, the mortality risk is very low. Giving a single universal figure here would be misleading, because risk depends substantially on cardiovascular health, age, and individual factors that a surgical team evaluates during pre-operative assessment. What the evidence consistently shows is that careful patient selection and pre-operative health review are the primary mechanisms through which that risk is managed — not assumed away.

Modern anaesthesia has shifted considerably over recent decades. Multimodal protocols — combining several agents at lower individual doses rather than relying on a single deep general anaesthetic — have improved how patients feel in the hours after surgery and reduced physiological stress during the procedure. Same-day mobilisation, getting patients upright on the day of the operation, is now standard in well-structured care pathways rather than the exception.

Infection is worth raising directly rather than minimising. The risk is real, and good surgical teams address it systematically: antibiotic prophylaxis, pre-operative skin preparation, theatre protocols, and attention to underlying conditions such as poorly controlled diabetes that are known to raise infection vulnerability. Pre-operative optimisation — in some cases, reaching a stable HbA1c before a theatre date is confirmed — is a clinical safeguard, not bureaucracy.

The comparison that matters most is not surgical risk measured in isolation, but surgical risk weighed against what prolonged painful immobility costs across months and years of deferred treatment. For patients whose conservative management has stopped working, that balance tends to shift considerably.

Dislocation: a fear that surgical technique has transformed

Of all the specific complications patients mention, dislocation occupies a particular place in hip replacement anxiety — and historically, that concern had genuine clinical weight behind it.

In traditional posterior total hip arthroplasty, the approach involves dividing the posterior tendons and capsule to reach the joint. This removes a key structural check: the tendons that wrap around the back of the hip and help keep the femoral head in place. Once cut and repaired at closure, they heal as scar tissue rather than native tissue — and the proprioceptive feedback they carried (the joint's continuous sense of its own position) is disrupted along with them.

The numbers attached to dislocation after traditional posterior approaches are not trivial. Of patients who dislocate, 57% go on to experience more than one event, and 45.6% of that group require complex revision surgery within two years — a significant burden arising from what was intended as a primary elective operation.

The SPAIRE technique, developed and routinely used by Professor Paul Lee, takes a different course. By preserving the piriformis and obturator internus tendons intact, and repairing the obturator externus, the posterior soft-tissue architecture remains as a functioning mechanical strap against dislocation. Because the tendons are not divided, the proprioceptive receptors embedded within them — Golgi tendon organs and muscle spindles — continue relaying positional information to the central nervous system, which may support both structural stability and confident early movement in the days after surgery.

Dislocation risk is not a fixed quantity across all hip replacements. It depends substantially on surgical approach and whether the posterior soft tissues are preserved or divided. Any patient weighing this concern can and should ask that question directly when discussing technique.

Age as a barrier: too young, too old, or neither

Both age fears point in opposite directions but share the same flaw: they treat age as the governing variable when it is not.

The younger patient's concern

The worry that an implant placed in the 40s or 50s will wear out and require a technically more complex revision operation has genuine clinical logic. Under-50 patients typically place higher mechanical demands on a prosthesis through more active daily lives, and longevity is not unlimited. Modern implants carry a documented 90% survivorship at 15 years, and with appropriate technique and implant selection, longevity beyond 30 years is achievable rather than aspirational. What that evidence argues for is sequencing, not avoidance. For under-60 patients, exhausting joint-preservation options first — physiotherapy, targeted injections, and in selected cases osteotomy — represents an appropriate first chapter. Many patients who eventually proceeded after years of conservative management report that they wish they had reached that decision sooner. The comparison is not implant lifespan measured against a fixed clock; it is quality of daily life during the years spent waiting.

The older patient's concern

There is no official upper age cut-off for hip replacement. Eligibility rests on cardiovascular fitness and overall health, not chronological age. NHS data from England for 2020/21 shows the highest volume of hip replacements was performed in women aged 75–79, and outcomes in older cohorts are documented as equal to or better than in younger groups. The idea that hip replacement is a procedure for the relatively young is not supported by what surgeons actually do, or by what the data shows about who benefits.

The productive question, for patients at either end of this range, is not whether they fall in the right age bracket. It is whether conservative management has genuinely been exhausted and whether the individual health profile makes surgery appropriate.

Recovery expectations: what has changed and what hasn't

Recovery from hip replacement carries a heavy mental image for many patients: a week in hospital, months of careful restriction, a slow return to ordinary movement. That image was accurate for an earlier era. It is not a reliable guide to what modern pathways make possible.

The link between surgical approach and recovery speed is direct. When posterior tendons are divided to reach the joint, the surrounding tissue needs time to heal before bearing load reliably. Muscle-sparing approaches that leave those structures intact reduce the initial disruption — less soft-tissue trauma means less post-operative pain, earlier confident movement, and a shorter path back to walking.

Within Professor Paul Lee's biological rapid recovery programme — which integrates implant selection, surgical technique, mobilisation timing, and post-operative care design — selected patients may be able to go home the same day or the following morning rather than after the traditional three-to-five-day inpatient stay. For those who meet the relevant health and anatomy criteria, mobilisation typically begins on the day of surgery itself. Unaided walking within the first few days is a realistic milestone within this pathway, and return to driving is generally possible around six weeks post-operatively for most patients.

Faster discharge does not mean less structured support. Physiotherapy is built into the pathway, milestones are defined, and patients receive clear guidance on what to expect at each stage.

It is worth asking any surgeon you consult what their specific recovery pathway involves — not just the operation itself, but the days and weeks surrounding it. Outcomes vary substantially by surgical approach, and the difference between a programme designed around early mobilisation and a conventional inpatient course is not a minor logistical detail.

What delay actually costs: the clinical case for honest timing

Choosing to wait is not the same as choosing neutrally. Every month spent deferring a hip replacement that is clinically indicated is a month in which the surrounding musculature continues to weaken, joint mechanics deteriorate further, and the eventual operation becomes technically more demanding. That accumulation is rarely how patients frame the decision when they decline to proceed — but it is how the evidence frames it.

The most directly relevant data comes from fracture patients rather than elective osteoarthritis cases, so extrapolation should be made carefully. A PMC study found that patients whose hip surgery was delayed beyond 21 days recorded meaningfully lower Harris Hip Scores at one year compared with those treated within seven days (85.2 versus 89.8, p<0.05), with functional recovery progressing more slowly throughout the follow-up period. The direction of this effect aligns with what is well established about deconditioning: muscle atrophy, reduced cardiovascular reserve, and restricted range of movement accumulated during a long wait do not simply resolve once the new joint is in place.

One counterintuitive finding from the same study deserves particular attention. The delayed group reported higher satisfaction scores at follow-up — not lower. The likely explanation is that extended suffering recalibrated what patients expected from the outcome. Gratitude after a long ordeal is real, but it is not a measure of optimal timing. Feeling relieved after eventually recovering does not mean that the years spent waiting represented the better clinical path.

Psychosocial factors — kinesiophobia (fear of damaging the joint by moving it), catastrophising about pain, and limited practical support at home — are documented drivers of hesitation. They are worth naming honestly rather than dismissing, because they are amenable to specific support: clear pre-operative education, physiotherapy designed to rebuild confidence in movement, and straightforward planning around the recovery period. These are not reasons to avoid surgery indefinitely; they are problems with solutions.

When conservative management has been genuinely, systematically exhausted — when physiotherapy, weight management, and appropriate injections have all been tried and symptoms continue to worsen — the clinical case for ongoing delay becomes harder to sustain. At that point, the question shifts from 'am I ready to consider surgery?' to 'what is the cost of not acting?' Specialist assessment, based on current symptoms, imaging, and functional history, is the appropriate next step for anyone who has reached that stage without a clear answer.